Overview

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma

Status:
Not yet recruiting

Trial end date:
2025-12-30

Target enrollment:

Participant gender:

Summary

This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed and/or refractory multiple myeloma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Beijing InnoCare Pharma Tech Co., Ltd.